Article Excerpt:
TWST: We'd like to begin with a brief historical sketch of MedMira and a picture of the things you are doing at the present time.Mr. Chan: MedMira was started in 1994 by my wife and myself. We are the original inventors of MedMira's current technology platform, the rapid flow-through technology. We began with the development of our flagship product, which is the rapid HIV test that currently has received four major approvals, including the United States, Canada, China, and Europe. Our technology platforms set us apart from the rest of the pack. We partnered in 1994 with an entrepreneur named Mr. Stephen Sham, who served as the CEO and the Chairman for the last 12 years, and recently he retired as the CEO but remains as the Chairman of the Board. He has provided much of the financing to develop our technology and the current applications. We became publicly traded in 2000. We continue to develop new diagnostic applications for our technology platform and recently launched our multiple tests for HIV and Hepatitis C at the International AIDS Conference in Toronto. This rapid test is the first of its kind in the world.
TWST: Would you explain the multiple test?
Mr. Chan: The multiple test is built on the flow-through technology platform
that we invented and developed. It will simultaneously detect both HIV
antibodies and Hepatitis C antibodies in a matter of three minutes, and it will
simultaneously give the result in this time frame.
Tickers included in this excerpt: MIR:TSX.V
TWST Newsletter
For more information call (212) 952 7433. The Wall Street Transcript does not endorse any of the comments made by interviewees, and does not make stock recommendations.